Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Distinct expression profiles of soft tissue sarcomas

PROVIDER: PRJNA237519 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR1163240.fastq.gz	Fastqsanger.gz
	SRR1163250.fastq.gz	Fastqsanger.gz
	SRR1163260.fastq.gz	Fastqsanger.gz
	SRR1163270.fastq.gz	Fastqsanger.gz
	SRR1163280.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 45

Similar Datasets

Homo sapiens

Project description:Expression data from human soft tissue sarcomas with complex genomics

| PRJNA130471 | ENA

Homo sapiens

Project description:MicroRNA profiling of primary high-grade soft tissue sarcomas

| PRJNA157439 | ENA

Homo sapiens

Project description:Gene Expression Analysis of Soft Tissue Sarcomas: Characterization & Reclassification of Malignant Fibrous Histiocytoma

| PRJNA98725 | ENA

Homo sapiens

Project description:Gene expression of Alveolar Soft Part Sarcomas [mRNA]

| PRJNA196831 | ENA

Homo sapiens

Project description:Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas [gene expression]

| PRJNA227805 | ENA

Heterogeneity in the gene regulatory landscape of leiomyosarcoma

Project description:Soft-tissue sarcomas are group of rare, tremendously heterogeneous, and highly aggressive malignancies. Characterizing inter-tumor heterogeneity is crucial for selecting suitable sarcoma therapy, as the presence of diverse molecular subgroups of patients can be associated with disease outcome or response to treatment. While cancer subtypes are often characterized by differences in gene expression, the mechanisms that drive these differences are generally unknown. We therefore set out to model the regulatory mechanisms driving sarcoma heterogeneity. We subtyped soft-tissue sarcomas based on patient-specific, genome-wide gene regulatory networks and found pronounced regulatory heterogeneity in leiomyosarcoma—one of the most common soft-tissue sarcomas subtypes that arises in smooth muscle tissue.

2023-07-25 | GSE218533 | GEO

Homo sapiens

Project description:Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas [methylation]

| PRJNA227804 | ENA

Homo sapiens

Project description:Heterogeneous genetic profiles in soft tissue myoepitheliomas

| PRJNA108463 | ENA

Transcriptomic analysis of 162 myxofibrosarcomas and undifferentiated pleomorphic sarcomas

Project description:The global gene expression profiles of 162 myxofibrosarcomas and undifferentiated pleomorphic sarcomas were studied by RNA-sequencing. The profiles were compared with clinical and genomic features. 21 soft tissue tumors of other histotypes were used as out-group.

2024-09-30 | E-MTAB-13947 | biostudies-arrayexpress

A lncRNA HAR1B has a potential as a predictive marker for pazopanib therapy in patients with sarcoma

Project description:Bone and soft tissue sarcomas are rare and highly heterogeneous mesenchymal malignancies. Their rarity makes it difficult to acquire clinical data of patients with specific histological subtypes of sarcoma from large clinical trials. The diagnoses and treatment of sarcomas need to be further developed. We show that a long non-coding RNA (lncRNA) HAR1B may serve as predictive biomarkers for pazopanib treatment in bone and soft tissue sarcomas. Multiplex real-time reverse transcription polymerase chain reaction and microarray analyses revealed that HAR1B and HOTAIR were differentially expressed in pazopanib-sensitive cells and responders. We further clarified this mechanism by showing that siRNA-knockdown of HAR1B led to an increased resistance to pazopanib in sarcoma cell lines. Gene expression profiles related to pazopanib sensitivity included cellular molecular pathways, including genes involved in von-Willebrand factor-related signaling. Our study demonstrates that lncRNA HAR1B expression affects cellular sensitivity to pazopanib in sarcoma cell lines and in patients with sarcoma.

2021-04-28 | GSE156344 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data